CLGNNasdaqOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
CollPlant Biotechnologies Ltd
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 26, 2026
$3.56−0.06 (-1.79%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
CollPlant Biotechnologies Ltd revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenues from milestones [Member] | $2.00M | – | $10.00M | – | – | – | – | – | 84.4% | – |
| Revenues from the Sales of Goods [Member] | $371.00K | $515.00K | $959.00K | $299.00K | $1.60M | – | – | – | 15.6% | -28.0% |
| Revenues from licensing agreement [Member] | – | – | $10.00M | – | $14.00M | – | – | – | – | – |
| Revenues from the rendering of services [Member] | – | – | – | – | $46.00K | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| United States | $2.18M | $484.00K | $10.84M | $16.00K | $14.95M | $5.77M | $2.08M | $4.87M | 91.8% | +349.6% |
| Europe and others [Member] | $98.00K | – | $28.00K | $104.00K | $633.00K | – | – | – | 4.1% | – |
| Canada | $96.00K | – | $87.00K | $158.00K | $57.00K | – | – | – | 4.0% | – |
| Israel | $1.00K | $31.00K | $5.00K | $21.00K | – | – | – | – | 0.0% | -96.8% |
| Total [Member] | – | – | – | $299.00K | $15.64M | $6.14M | $2.32M | $5.01M | – | – |
| Europe and others [Member] | – | – | – | $125.00K | $628.00K | $369.00K | $240.00K | – | – | – |
From the segment and revenue-disaggregation notes of CollPlant Biotechnologies's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.